Vincent Chien-Huai Chuang

Medical oncologist, National Taiwan University Cancer Center

[Hong Jae Chon @hongjaechon]

🔥Early promising signals in heavily pretreated HCC #ASCO26 @ASCO
Phase 1 Trial of BGB-B2033 (GPC3 x 4-1BB Bispecific Antibody) Monotherapy in Selected Advanced or Metastatic Solid Tumors
👉60/61 heavily pretreated HCC patients (98.4%).
👉Only 8.2% grade ≥3 TRAEs
👉Confirmed ORR of 28.9% at doses ≥300 mg
👏Registration-enabling studies in development.
Abstract: https://t.co/BoJGxrzQxU

[Stephen V Liu, MD @StephenVLiu]

Dr. @FSkoulidis #ASCO26: Krascendo 170 - first-line divarasib + pembrolizumab in KRAS G12C NSCLC. In PDL1+, RR 73%, mPFS 19.3m! In PDL1-, unconfirmed RR 70%. Impressive efficacy and DCR.

[Vincent Chien-Huai Chuang @vincent_huai]

How about colon cancer?
ctDNA(-) at TP#1: 1,915
Converted to ctDNA (+) at TP#2: 56
supporting the concept serial ctDNA testing can detect early molecular recurrence, but the evidence that adjuvant chemo improves DFS in TP#2-converted patients is limited by small number

[Vincent Chien-Huai Chuang @vincent_huai]

dynamic biomarker-selected intensification strategy for EGFRmt NSCLC is coming?

[Angela Lamarca @DrAngelaLamarca]

Liver #biopsy in suspected #HCC data presented at @EASLnews #LiverCancerSummit 2025 in Paris by Blase et al

5% are other histology - some being #CCA (this has huge implications for those individual patients!)

No tumour seeding identified 😉

Personally, in favour of biopsy 🙋🏻‍♀️

[Ronan Hsieh, MD, MS @ronanhsieh]

Promising data. From a cross trial comparison, single agent (44%) had a lower pCR than the numbers for Nivo ipi in NICHE and Bol Bal.

[Vincent Chien-Huai Chuang @vincent_huai]

Could TIGIT blockade be the next breakthrough in esophageal cancer?

https://t.co/qgAG9gp92Z

[Arndt Vogel @ArndtVogel]

ESMO GI 2024 take-home messages: Oligometastatic pancreatic cancers #ESMOGI24
👉Separating facts from wishful thinking
👉Definition, pathogenesis, natural history, role of surgery, patient selection...
@myESMO #ESMOAmbassadors

[Tsung-Che Wu @TsungCheWu]

https://t.co/AMy0gSkh0V
SKYSCRAPER-08, presented by my mentor Prof Chih-Hung Hsu
1st +ve ph3 with an Anti-Tigit
Atezo/Tira + TP vs TP
OS 15.7M/11.1M HR:0.70 PFS 6.2M/5.4M HR:0.56
However, the exact role of anti-Tigit component is not yet clear #GI24 #GIcancer #esocsm #gicsm

[Antonio D'Alessio @A_DAlessioMD]

🌁 It's a pleasure to present the first global, cross-trial study looking at the role of pathological response as surrogate endpoint for RFS in early-stage HCC receiving neoadjuvant ICI 🩺
Come say hi at Board D13 📃 @DJPinato @ASCO @ImperialSandC @UniAvogadro @LorenzaRimassa

[Vincent Chien-Huai Chuang @vincent_huai]

@LorenzaRimassa @ASCO @HUNIMED @HumanitasMilano Appreciate your insights!

[Bernard A Fox @BernardAFox]

@genentech @Roche 3) 💥 #TLS HAVE IMPACT! Could lead to sparing #NSCLC patients treatment with #chemotherapy /#Impower110 TLS+ improved PFS & OS/N.B. It is a Retrospective analysis/BUT IMPRESSIVE! #SITC2023 #cancer #immunotherapy @LungSummit @LungCancerFaces @GO2forLungCancr @NSCLC_cancer #lung

[Society for Immunotherapy of Cancer @sitcancer]

Day 2 of #SITC23 starts with the inaugural SITC Fun Run. Thanks to all who participated. What an incredible turnout! A great way to kick off another incredible day of science and cancer #immunotherapy.

[JAMA Oncology @JAMAOnc]

Immune checkpoint inhibitor avelumab was compared to standard 2nd line treatment for deficient mismatch repair &/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer & demonstrated significantly better PFS & disease control duration https://t.co/eh09FgEkcW #CRCSM

[Vincent Chien-Huai Chuang @vincent_huai]

Had an enlightening discussion with Prof. Yoshino and colleagues today. Grateful for the opportunity to exchange ideas and learn from such intellectual minds! #ASCOBT

[JCOG @JCOG_official]

#JCOG の研究グループのご紹介 -#肝胆膵 グループ編-

#肝がん ・ #胆道がん ・ #膵がん は、罹患数に対し死亡数が多く、極めて予後不良の疾患であり、より有効な #標準治療 の確立が望まれてい��す。

2008年4月に発足し、#臨床試験 を積極的に推進しています。

https://t.co/85Q3VOjObp

[Arndt Vogel @ArndtVogel]

Phase 2 Study of Futibatinib in pts With FGFR Aberrations: Activity in Patients With GC/GEJ Cancer Harboring FGFR2 Amplification at #WCGIC23
👉Only modest activity in heavily pretreated pts
👉Amplifications also challenging in BTC
@myESMO @WCGIC @OncoAlert

[Vincent Chien-Huai Chuang @vincent_huai]

Very challenging for MSS mCRC.

[Arndt Vogel @ArndtVogel]

Lenvatinib Plus Pembrolizumab vs Regorafenib or TAS for Previously Treated mCRC: Phase 3 LEAP-017 Study at #WCGIC2023
👉mOS: 9.8 vs 9.3 mo
👉There is some activity, but⛔️
👉IO in MSS CRC remains a challenge...
@WCGIC @myESMO @OncoAlert

[Yelena Y. Janjigian MD @YJanjigianMD]

Excited to finally share that Keynote 811 survival data in first line HER2+ gastroesophageal cancer will be presented at @myESMO @MSKCancerCenter @MSK_DeptOfMed
https://t.co/uxKYFNMNMT

[Vincent Chien-Huai Chuang @vincent_huai]

Very excited to participate the meeting !

[Stephen L. Chan @StephenLChan1]

There are over 200 registrations (both virtual and on-site). We look forward to seeing you!